Houlihan Lokey HLI · NYSE
$133.27 +3.80% (+$4.88)
Summary
67 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 10 years in a row and pays out only 45% of profit.
- Out of every 100 USD of revenue, 16 USD is left as net profit.
- Analysts expect revenue to grow by 11% this fiscal year.
What to watch
- Revenue growth is slowing: 1.7% a year over the last 3 years against 16% over 5 years.
- You pay 22.9 USD for 1 USD of yearly profit, a lot for its sector.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 22.9 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 1.7% a year. For the next fiscal year analysts expect revenue to grow by 11%. Earnings per share fell by 3.2% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 49 USD
- Sales and administration 29 USD
- Taxes and other 5.7 USD
- Net profit 16 USD
Net profit, industry median (Investment - Banking & Investment Services) 18 USD
Out of every 100 USD of revenue, 16 USD is left as net profit.
Profitability in detailIs it financially healthy?
Banks and insurers work with their customers' money, so their debt is judged differently; see the health section for their capital figures.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.95%
- Paid out of profit
- 45%
- Raised in a row
- 10 years
You receive $2.60 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 10
- Hold 5
- Sell 1
Today's price within the analysts' price targets
The average target of $162.2 is 22% above today's price. 63% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Corporate Finance 77%
- Financial Restructuring 23%
By region
- UNITED STATES 68%
- Non-US 32%
Corporate Finance brings in 77% of revenue. Financial Restructuring grew fastest, by 7.7% a year.
Segments in detail